Respiratory distress syndrome.
Increasing knowledge of the pathophysiology of respiratory distress syndrome has led to improvements in clinical management. Future advances in prevention and therapy, including administration of agents to prevent prematurity or to accelerate lung maturation, provision of surfactant replacement, and new techniques of mechanical ventilation, will further decrease mortality and morbidity.
D000818:Animals; D003422:Critical Care; D004231:Diuresis; D004232:Diuretics / Q000627:therapeutic use; D004374:Ductus Arteriosus, Patent / Q000503:physiopathology; D005260:Female; D005346:Fibroblast Growth Factors / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000503:physiopathology*; D008297:Male; D009466:Neuromuscular Blocking Agents / Q000627:therapeutic use; D010102:Oxygen Inhalation Therapy; D010713:Phosphatidylcholines / Q000032:analysis; D011296:Prenatal Diagnosis; D011654:Pulmonary Edema / Q000503:physiopathology; D011663:Pulmonary Surfactants / Q000502:physiology / Q000627:therapeutic use; D051381:Rats; D012121:Respiration, Artificial / Q000379:methods; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D012306:Risk; D013109:Sphingomyelins / Q000032:analysis
D004232:Diuretics; D009466:Neuromuscular Blocking Agents; D010713:Phosphatidylcholines; D011663:Pulmonary Surfactants; D013109:Sphingomyelins; C044220:fibroblast pneumonocyte factor; D005346:Fibroblast Growth Factors